Literature DB >> 31477957

Prevalence of Depression in Patients with Chronic Kidney Disease Stage 5 on Hemodialysis at a Tertiary Care Center.

Krishna Kumar Agrawaal1, Pramod Kumar Chhetri1, Pradip Man Singh2, Dhiraj Narayan Manandhar1, Prakash Poudel1, Anjeel Chhetri2.   

Abstract

INTRODUCTION: Co-morbid depression impacts negatively on quality of life in Chronic Kidney Disease patients. This study was done to calculate prevalence of depression in patients on hemodialysis (HD) using Patient Health Questionnaire-9, Hamilton Rating Scale for Depression-17 and International Classification of Disease-10 classification of mental and behavioural disorders.
METHODS: It was descriptive cross-sectional study conducted from November 2017 till June 2018. Ethical approval was taken from Ethical Review Board, Nepal Health Research Council. Informed and written consent was taken. Patients undergoing hemodialysis at Nepal Medical College for more than 3 months duration were included in study. Patients on hemodialysis were asked to fill validated Nepali translated version of Patient Health Questionnaire-9. Psychiatrist administered Max Hamilton Rating scale for diagnosis and categorization of depression and confirmed depression based on International Classification of Disease-10. Statistical Package for Social Sciences version 20 was used for statistical analysis.
RESULTS: The study was done among 100 patients. Prevalence of depression was 78 (78%) using Patient Health Questionnaire-9 and 65 (65%) using Max Hamilton Rating scale and 51 (51%) using International Classification of Disease -10. Mean depression in males using Patient Health Questionnaire -9 was 7±4.33 and in females was 11.04±5.90. Median age was 47.5 years. The most common symptom was fatigue among 82 (82%).
CONCLUSIONS: There is a high prevalence of depression in patients with Chronic Kidney Disease stage 5 on hemodialysis compared to general population.

Entities:  

Keywords:  depression; hemodialysis; Nepal.

Mesh:

Year:  2019        PMID: 31477957      PMCID: PMC8827512     

Source DB:  PubMed          Journal:  JNMA J Nepal Med Assoc        ISSN: 0028-2715            Impact factor:   0.406


INTRODUCTION

Depression is the most common psychiatric problem in Chronic Kidney disease (CKD) patients. Co-morbid depression impacts negatively on quality of life in CKD.[1] It is unclear if self-reported depression rating scales can be used accurately. There are different scales used in dialysis patients like Beck Depression Inventory (BDI) and Quick Inventory of Depression Symptomatology (QIDS-SR).[2,3] In meta-analysis by Stripolli et al. it was found that using self- or clinician-administered rating scales, prevalence of depressive symptoms for CKD stage 5 was higher than other stages.[4] The BDI, Hamilton Rating Scale for Depression (HAD-17), Nine-Question Patient Health Questionnaire (PHQ-9) are some of measures that have been used to screen for depression in patients with end-stage renal disease (ESRD).[5] In study conducted in Nepal, PHQ-9 was validated for its use in depression. PHQ-9 is preferred tool for use in low and middle income countries (LMICs).[6] This study was done to calculate prevalence of depression in patients on hemodialysis (HD) using PHQ-9, HAD-17 and ICD-10 classification of mental and behavioural disorders.

METHODS

This descriptive cross-sectional study was conducted at Nepal Medical College, Kathmandu from November 2017 till June 2018. Ethical approval was taken from Ethical Review Board, Nepal Health Research Council. Sample size was calculated using the sample size calculation formula: where, n = required sample size Z = 1.96 at 95% Confidence Interval P = estimated prevalence of ESRD population (5% taking an account of increase in prevalence from previous studies) q = 1-p d = allowable error, 5% Based on the above formula the minimum estimated sample size at 95% confidence interval and 5% error, total sample size calculated was 73. Taking non-response rate of 10%, the calculate sample size is 80. We took 100 patients in the study. Patients above the age of 18 years, those giving informed written consent to be enrolled in study and on HD at Nepal Medical College more than 3 months duration were included in the study. Patients on HD were asked to fill the Nepali translated version of PHQ-9 questionnaire, which is already validated tool for screening and diagnosis of depression. The patients took approximately one minute to fill the PHQ-9 and were not allowed to cross talk. The psychiatrist administered Max Hamilton Rating scale for the diagnosis and categorization of depression. Psychiatrist also confirmed the depression diagnosis with personal interview with each patient in the dialysis unit itself and labelled them based on ICD-10 classification of mental and behavioural disorders (Diagnostic criteria for research). SPSS v. 20 was used for statistical analysis.

RESULTS

Total number of patients included in final analysis were 100. Male: Female ratio was 1.21:1 (Table 1).
Table 1.

Showing baseline characteristics of patients (n=100).

CharacteristicsCategoriesn (%)
Age<20 years1 (1)
20-39 years35 (35)
40-59 years36 (36)
≥60 years28 (28)
Median age in years (IQR)47.5 (33.0 – 60.75)
Duration since dialysis3-6 months9 (9)
7-12 months22 (22)
13-24 months33 (33)
25-48 months20 (20)
>48 months16 (16)
Median duration since HD in months (IQR)24.0 (9.25-36.00)
PHQ-9 Total scores<1063 (63)
≥1037 (37)
≥1516 (16)
≥205 (5)
Mean PHQ-9 score and HAD-17 score was 8.86±5.48 and 12.33± 7.01 respectively. Most common symptom was fatigue 82 (82%) based on PHQ-9 (Table 2).
Table 2.

Showing frequencies of different symptoms of PHQ-9 (n=100).

Charactersticsn (%)
Anhedonia65 (65)
Depressed mood67 (67)
Sleeping difficulties56 (56)
Fatigue82 (82)
Appetite problems61 (61)
Blaming oneself53 (53)
Concentrating difficulties46 (46)
Psychomotor agitation82 (82)
Suicidal ideation45 (45)
Grading of depression based on PHQ-9 and HAD-17 and ICD-10 (Table 3).
Table 3.

Level of Depression using different scales (n = 100).

Level of DepressionGradingn (%)
Based on PHQ-9Minimal22 (22)
Mild41 (41)
Moderate21 (21)
Moderately11 (11)
Severe
Severe5 (5)
based on MaxNormal35 (35)
Hamilton scoreMild22 (22)
(HAD-17)Moderate18 (18)
Severe21 (21)
Very Severe4 (4)
based on ICD-10No Depression49 (49)
Mild Depressive13 (13)
Episode without
Somatic
Syndrome
Mild Depressive2 (2)
Episode with
Somatic
Syndrome
Moderate7 (7)
Depressive
Episode without
Somatic
Syndrome
Moderate13 (13)
Depressive
Episode with
Somatic
Syndrome
Severe16 (16)
Depressive
episode without
psychotic
symptoms
Prevalence of depression using PHQ-9, HAD-17 and ICD-10 was 78%, 65% and 51% respectively. Mean depression in males using PHQ-9 was 7±4.33 and in females was 11.04±5.90. Similarly, the mean depression in males using HAD-17 score was 11.76±6.75 and in females was 13.00±7.32 with CI ranging from 1.55 to 4.03.

DISCUSSION

In this series of 100 patients on HD at Nepal Medical College, we enrolled patients who were in Nepal Governments' Bipanna Program i.e. free HD services. We excluded patients who received HD out of pocket to eliminate the economic confounding factor leading to depression. The median age of patients was 47 years which is similar to study in BPKIHS and previous study at NMCTH.[7,8] In our study, age had no impact on depression as there was no difference in means. Women had more instances of depression which was comparable to other studies.[9,10] The median duration of dialysis patients in this study was 24 months. In a study done by Khaled et al, found that fatigue was the most common symptoms in patients with dialysis and this was similar in our study. They also compared PHQ-9 with 30 item dialysis symptom index and found that a median of PHQ-9 score of more than 9 is comparable.[11] The mean PHQ-9 score in our study was 9 which is comparable to other studies. Here we used HAD-17 score which is considered as a standard for depression screening. No direct comparison has been done till date in ESRD population but in a study by Williams et al. in Parkinson patient with depression they compared three clinician led scales.[12] Overall prevalence of depression in our series was 78% using PHQ-9 score and the 65% using HAD-17 scores. Around 16% of the patients had severe depression in patients using the PHQ-9 and 25% had severe depression using the HAD-17 scores. The patients' self administered the proforma for PHQ-9 but HAD-17 was filled by the psychiatrist and final diagnosis was made by the psychiatrist himself. This might have led to exclusion of patient who had mild depression on PHQ-9 scale. Similarly the HAD-17 score also labelled most of the patients as no depression who were having mild depression on PHQ-9. This may have caused the difference in the prevalence of depression using the different tools. The advantage of PHQ-9 was that it was self administered and took approximately a minute to fill by the patient but biggest disadvantage was its low specificity which was similar in other studies.[13,14] Based on the above presented results and comparing other studies with PHQ-9, it is found that the scale is having good sensitivity and due to its easy administration, it can be used to screen the patients but once the score of PHQ-9 is >9 the patients need to be subjected for psychiatric evaluation. The depression adds to morbidity and mortality to patients hence this cost effective tool can be used.

CONCLUSIONS

There is a high prevalence of depression in patients on hemodialysis compared to general population. Patients with score >9 on PHQ-9 can be subjected to HAD-17 scale and if facilities available diagnosis should be confirmed by psychiatrist.
  11 in total

1.  A comparison of nine scales to detect depression in Parkinson disease: which scale to use?

Authors:  J R Williams; E S Hirsch; K Anderson; A L Bush; S R Goldstein; S Grill; S Lehmann; J T Little; R L Margolis; J Palanci; G Pontone; H Weiss; P Rabins; L Marsh
Journal:  Neurology       Date:  2012-03-14       Impact factor: 9.910

Review 2.  Depression in dialysis patients.

Authors:  Terry King-Wing Ma; Philip Kam-Tao Li
Journal:  Nephrology (Carlton)       Date:  2016-08       Impact factor: 2.506

3.  Performance of the PHQ-9 as a screening tool for depression after stroke.

Authors:  Linda S Williams; Edward J Brizendine; Laurie Plue; Tamilyn Bakas; Wanzhu Tu; Hugh Hendrie; Kurt Kroenke
Journal:  Stroke       Date:  2005-01-27       Impact factor: 7.914

Review 4.  Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies.

Authors:  Suetonia Palmer; Mariacristina Vecchio; Jonathan C Craig; Marcello Tonelli; David W Johnson; Antonio Nicolucci; Fabio Pellegrini; Valeria Saglimbene; Giancarlo Logroscino; Steven Fishbane; Giovanni F M Strippoli
Journal:  Kidney Int       Date:  2013-03-13       Impact factor: 10.612

5.  In-center hemodialysis for end stage kidney disease at Nepal Medical College and Teaching Hospital.

Authors:  P K Chhetri; D N Manandhar; R Tiwari; S Lamichhane
Journal:  Nepal Med Coll J       Date:  2009-03

6.  Symptom burden, depression, and quality of life in chronic and end-stage kidney disease.

Authors:  Khaled Abdel-Kader; Mark L Unruh; Steven D Weisbord
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

Review 7.  Screening, diagnosis, and treatment of depression in patients with end-stage renal disease.

Authors:  Scott D Cohen; Lorenzo Norris; Kimberly Acquaviva; Rolf A Peterson; Paul L Kimmel
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 8.237

Review 8.  Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management.

Authors:  Shayan Shirazian; Candace D Grant; Olufemi Aina; Joseph Mattana; Farah Khorassani; Ana C Ricardo
Journal:  Kidney Int Rep       Date:  2016-09-20

9.  Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal.

Authors:  Brandon A Kohrt; Nagendra P Luitel; Prakash Acharya; Mark J D Jordans
Journal:  BMC Psychiatry       Date:  2016-03-08       Impact factor: 3.630

10.  Assessment of depression severity with the PHQ-9 in cancer patients and in the general population.

Authors:  Andreas Hinz; Anja Mehnert; Rüya-Daniela Kocalevent; Elmar Brähler; Thomas Forkmann; Susanne Singer; Thomas Schulte
Journal:  BMC Psychiatry       Date:  2016-02-02       Impact factor: 3.630

View more
  1 in total

1.  Effects of Testosterone Treatment on Quality of Life in Patients With Chronic Kidney Disease.

Authors:  Jeong Kyun Yeo; Ho Seok Koo; Jihyeong Yu; Min Gu Park
Journal:  Am J Mens Health       Date:  2020 May-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.